Update on quetiapine in the treatment of bipolar disorder: results from the BOLDER studies

Prashant Gajwani1, David J Muzina2, David E Kemp3, Keming Gao1, Joseph R Calabrese11Case Western Reserve University (CWRU) School of Medicine, 2Cleveland Clinic Lerner College of Medicine of CWRU, 3Case Western Reserve University, Cleveland OH, USAAbstract: The essential features of bipolar affectiv...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Prashant Gajwani, David J Muzina, David E Kemp, Keming Gao, Joseph R Calabrese
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2007
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/05c22c74891d4858a3d09afe0db2ebd1
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:05c22c74891d4858a3d09afe0db2ebd1
record_format	dspace
spelling	oai:doaj.org-article:05c22c74891d4858a3d09afe0db2ebd12021-12-02T02:35:55ZUpdate on quetiapine in the treatment of bipolar disorder: results from the BOLDER studies1176-63281178-2021https://doaj.org/article/05c22c74891d4858a3d09afe0db2ebd12007-01-01T00:00:00Zhttp://www.dovepress.com/update-on-quetiapine-in-the-treatment-of-bipolar-disorder-results-from-a963https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021Prashant Gajwani1, David J Muzina2, David E Kemp3, Keming Gao1, Joseph R Calabrese11Case Western Reserve University (CWRU) School of Medicine, 2Cleveland Clinic Lerner College of Medicine of CWRU, 3Case Western Reserve University, Cleveland OH, USAAbstract: The essential features of bipolar affective disorder involve the cyclical occurrence of high (manic or hypomanic episodes) and low mood states. Depressive episodes in both bipolar I and II disorder are more numerous and last for longer duration than either manic or hypomanic episodes. In addition depressive episodes are associated with higher morbidity and mortality. While multiple agents, including all 5 atypical antipsychotics, have demonstrated efficacy and earned US FDA indication for manic phase of bipolar illness, the acute treatment of bipolar depression is less well-studied. The first treatment approved by the US FDA for acute bipolar depression was the combination of the atypical antipsychotic olanzapine and the antidepressant fluoxetine. Recently, quetiapine monotherapy has demonstrated efficacy in the treatment of depressive episodes associated with both bipolar I and II disorder and has earned US FDA indication for the same.Keywords: bipolar disorder, quetiapine, BOLDER studies Prashant GajwaniDavid J MuzinaDavid E KempKeming GaoJoseph R CalabreseDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2007, Iss Issue 6, Pp 847-853 (2007)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Prashant Gajwani David J Muzina David E Kemp Keming Gao Joseph R Calabrese Update on quetiapine in the treatment of bipolar disorder: results from the BOLDER studies
description	Prashant Gajwani1, David J Muzina2, David E Kemp3, Keming Gao1, Joseph R Calabrese11Case Western Reserve University (CWRU) School of Medicine, 2Cleveland Clinic Lerner College of Medicine of CWRU, 3Case Western Reserve University, Cleveland OH, USAAbstract: The essential features of bipolar affective disorder involve the cyclical occurrence of high (manic or hypomanic episodes) and low mood states. Depressive episodes in both bipolar I and II disorder are more numerous and last for longer duration than either manic or hypomanic episodes. In addition depressive episodes are associated with higher morbidity and mortality. While multiple agents, including all 5 atypical antipsychotics, have demonstrated efficacy and earned US FDA indication for manic phase of bipolar illness, the acute treatment of bipolar depression is less well-studied. The first treatment approved by the US FDA for acute bipolar depression was the combination of the atypical antipsychotic olanzapine and the antidepressant fluoxetine. Recently, quetiapine monotherapy has demonstrated efficacy in the treatment of depressive episodes associated with both bipolar I and II disorder and has earned US FDA indication for the same.Keywords: bipolar disorder, quetiapine, BOLDER studies
format	article
author	Prashant Gajwani David J Muzina David E Kemp Keming Gao Joseph R Calabrese
author_facet	Prashant Gajwani David J Muzina David E Kemp Keming Gao Joseph R Calabrese
author_sort	Prashant Gajwani
title	Update on quetiapine in the treatment of bipolar disorder: results from the BOLDER studies
title_short	Update on quetiapine in the treatment of bipolar disorder: results from the BOLDER studies
title_full	Update on quetiapine in the treatment of bipolar disorder: results from the BOLDER studies
title_fullStr	Update on quetiapine in the treatment of bipolar disorder: results from the BOLDER studies
title_full_unstemmed	Update on quetiapine in the treatment of bipolar disorder: results from the BOLDER studies
title_sort	update on quetiapine in the treatment of bipolar disorder: results from the bolder studies
publisher	Dove Medical Press
publishDate	2007
url	https://doaj.org/article/05c22c74891d4858a3d09afe0db2ebd1
work_keys_str_mv	AT prashantgajwani updateonquetiapineinthetreatmentofbipolardisorderresultsfromthebolderstudies AT davidjmuzina updateonquetiapineinthetreatmentofbipolardisorderresultsfromthebolderstudies AT davidekemp updateonquetiapineinthetreatmentofbipolardisorderresultsfromthebolderstudies AT keminggao updateonquetiapineinthetreatmentofbipolardisorderresultsfromthebolderstudies AT josephrcalabrese updateonquetiapineinthetreatmentofbipolardisorderresultsfromthebolderstudies
_version_	1718402325678129152

Update on quetiapine in the treatment of bipolar disorder: results from the BOLDER studies

Ejemplares similares